Novo Integrated Sciences, Inc. - NVOS Total Company Value-to-Revenue Ratio

Public company logo of novointegrated.com (NVOS)

Geopolitical instability and inflation are increasing the cost of maintaining centers, which is reflected in the EV-to-revenue dynamics for Novo Integrated Sciences (NVOS). The value expresses the current level of this metric. Business stability is based on a loyal patient flow, while strict government compliance and licensing create a robust defensive barrier that limits the entry of new players into the primary care sector.

NVOS: Novo Integrated Sciences Inc Company Value to Revenue 07/04/2022 - 11/20/2026

Novo Integrated Sciences Inc - analytical breakdowns and key metrics (NVOS)

- money and cash flow information:
Initial company analysis:Novo Integrated Sciences NVOS
Core merchandise of Novo Integrated Sciences, Inc.

For Novo Integrated Sciences (NVOS), the efficiency of clinic scaling and drug commercialization directly determines revenue dynamics, making the business valuation sensitive to operating expenses. An analysis of the EV/Sales multiple on the GURU.Markets platform allows for a comparison of market capitalization plus debt against sales volume, where a narrowing range of values signals trend stabilization and a potential breakout of quotes beyond standard deviation boundaries.

Competitor analysis for Novo Integrated Sciences

Enterprise Value-to-Revenue Multiple hcahealthcare.com|THC: EV/Sales Multiple|FMS - Total Company Value-to-Revenue Ratio|Company Value to Revenue SOLV|Encompass (EHC) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Universal Health Services, Inc. (UHS)|DaVita Inc. - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio RadNet Corp RDNT|EV/Sales Multiple Option Care OPCH|Surgery Partners Inc - EV/Sales Multiple|PINC (Premier Corp) - Company Value to Revenue Ratio|nationalvision.com (EYE) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Progyny|Company Value to Revenue ARDT|EV/Sales Multiple Select Medical Corporation|Company Value to Revenue ASTH (Astrana Health)|Company Value to Revenue Pediatrix MD|U.S. Physical Therapy - Company Value to Revenue|Business Value to Revenue PNTG|Organogenesis - EV/Sales Multiple|NUTX (Nutex Health) - Company Value to Revenue Ratio|AUNA (Auna) - Company Value to Revenue|Enterprise Value to Sales Volume SBC (SBC Medical Group Holdings)|Enterprise Value-to-Revenue Ratio Evolus, Inc.|Community Health Systems, Inc. (CYH) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Beauty Health (SKIN)|MediWound, Ltd. - Company Value to Revenue Ratio|EV/Sales Multiple BTMD (Biote)|Enterprise Value-to-Revenue Coefficient JYNT (The Joint Corp.)|DCGO - Enterprise Value-to-Revenue Ratio|PIII: Enterprise Value-to-Revenue Ratio|GANX: EV/Sales Multiple|Company Value to Revenue EUDA Health|BMGL (Basel Medical Group) - EV/Sales Multiple|CLGN - Enterprise Value-to-Sales Ratio|Enterprise Value-to-Revenue Ratio Cuprina Holdings (CUPR)|Total Company Value-to-Revenue Ratio Concord Medical Services|EV/Sales Multiple AMS (ashs.com)|MEDIROM Healthcare Group Inc. (MRM) - Enterprise Value-to-Revenue Multiple|ALBT: Company Value to Revenue|Business Value to Revenue DHAI (DIH Holding US Inc.)|XAGE (Carmell Therapeutics) - Company Value to Revenue|NIVF (NewGenIvf Group Limited) - Enterprise Value-to-Revenue Ratio|ATIP (ATI Physical Therapy Inc.) - EV/Sales Multiple|EV/Sales Multiple CareMax Inc.|Enterprise Value-to-Revenue Ratio Kindly MD Inc (KDLY)|Company Value to Revenue ModivCare Corp MODV|SunLink Health Systems, Inc. - Company Value to Revenue|imacholdings.comm (BACK) - Enterprise Value-to-Revenue Multiple